January 22, 2026, Dresden, Germany.
Altavo, a medtech startup in AI-based voice rehabilitation, successfully closed a Series A2 financing round on January 12, 2026. A European consortium led by Novalis Biotech and Beteiligungsmanagement Thüringen is investing € 3m into the development of Altavo’s innovative Artificial Voice.
Altavo’s Artificial Voice is designed to help voiceless people, for example after laryngectomy or during mechanical ventilation, regain their own, natural sounding voice. The “silent speech” technology developed for this purpose in collaboration with researchers at Dresden University of Technology, is based on non-invasive radar sensing and the latest AI algorithms.
In addition to the lead investors Novalis Biotech (Ghent, Belgium) and Beteiligungsmanagement Thüringen, participants in the current round include TGFS Technologiegründerfonds Sachsen, High-Tech Gründerfonds (HTGF), TUDAG TU Dresden AG, Ostwerk GmbH and individual private investors.
The current Series A2 will finance company development, clinical work, as well as development of the commercial product. Altavo’s technology has the potential to improve the quality of life of voiceless people and opens fundamentally new possibilities in silent human-machine interaction.
“We are grateful for the strong backing of our existing European group of investors, and are glad to welcome new investors to the round. With the A2 round we are excellently positioned for the next steps on the path to an Artificial Voice for voiceless people.”
Rudolf von Bünau, CEO and co-founder, Altavo
“Altavo’s development and clinical progress and the experienced leadership convinced us to join the A2 round – co-leading the round together with bm-t, the Thuringia state investment agency.”
Jaroslav Belotserkovsky, Investment Manager, Novalis Biotech
“Altavo remains a prime example for the translation of academic research in a startup company and for successful public funding in the central German region, across state boundaries. We are glad to be able to accompany the Altavo team in realizing their ambitious vision.”
Michael Thiele, Investment Manager, bm | t beteiligungsmanagement thüringen gmbh
and Sören Schuster, CEO, TGFS Technologiegründerfonds Sachsen
About Altavo
Altavo GmbH is a Dresden based medical device startup founded in February 2021. Based on non-invasive radar sensing and artificial intelligence, Altavo is developing prosthetics to improve the rehabilitation of aphonic and severely voice impaired patients. At its Dresden and Jena locations, Altavo currently employs a team of 16 with many years of experience in the fields of AI / data science, speech technology, radio frequency engineering, medical devices, and speech therapy.
Altavo is partnering with the Chair of Speech Technology and Cognitive Systems and the Chair of Radio Frequency Engineering at Dresden University of Technology. The collaboration is supported by a grant from the state of Saxony and co-financed by the European Union in the project “B3 / MUSIK” within the SEMECO Cluster for Future.